Home World News Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC World News Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 612 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC June 4, 2021 Test Detects Early Signs of Remaining Cancer in Kids Treated for... December 8, 2021 Nivolumab Improves Survival for Some Patients with Advanced Stomach Cancer October 20, 2020 The Childhood Cancer Data Initiative: Transforming the Pediatric Cancer Landscape through... August 15, 2019 Load more HOT NEWS Cliff Collapse Kills Woman Celebrating Breast Cancer Victory and 2 of... Turning the Life Sciences Vision into reality Re-Thinking Community 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free.
